

Ivan Borbath

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1243798/ivan-borbath-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

14,630
citations

24
h-index

63
g-index

63
ext. papers

17,309
ext. citations

7.7
avg, IF

5.26
L-index

#	Paper	IF	Citations
61	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.. <i>Journal of Neuroendocrinology</i> , 2022 , e13105	3.8	4
60	Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.. <i>Current Oncology</i> , 2022 , 29, 2422-2434	2.8	0
59	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.. <i>European Journal of Cancer</i> , 2022 , 168, 80-90	7.5	0
58	Granuloma formation within perihepatic lymphadenopathy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101504	2.4	
57	Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. <i>Nuclear Medicine Communications</i> , 2021 , 42, 747-754	1.6	2
56	Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. <i>Gastroenterology</i> , 2021 , 161, 899-909.e5	13.3	36
55	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 803-815	18.8	37
54	Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. <i>European Journal of Cancer</i> , 2021 , 157, 403-414	7.5	9
53	Infigratinib in patients with advanced cholangiocarcinoma with gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020 , 16, 2375-2384	3.6	24
52	Endoscopic ultrasound-guided radiofrequency ablation: An effective and safe alternative for the treatment of benign insulinoma. <i>Annales D'Endocrinologie</i> , 2020 , 81, 567-571	1.7	3
51	and mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cells. <i>Gut</i> , 2020 , 69, 704-714	19.2	14
50	Impact of needle-based confocal laser endomicroscopy on the therapeutic management of single pancreatic cystic lesions. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020 , 34, 2532-2540	5.2	7
49	Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. <i>Future Oncology</i> , 2019 , 15, 1219-1230	3.6	12
48	Sorafenib Reduced Significantly Hepatopulmonary Shunt in a Large Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 70-71	1.7	3
47	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 454-465	18.8	28
46	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919875568	5.4	73
45	Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 345-345	2.2	10

44	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019 , 108, 54-62	5.6	41
43	Risk of advanced lesions in patients with branch-duct IPMN and relative indications for surgery according to European evidence-based guidelines. <i>Digestive and Liver Disease</i> , 2019 , 51, 882-886	3.3	8
42	Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement. <i>Neuroendocrinology</i> , 2018 , 106, 158-166	5.6	30
41	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018 , 107, 237-245	5.6	32
40	Liver and Pancreas: Do Similar Embryonic Development and Tissue Organization Lead to Similar Mechanisms of Tumorigenesis?. <i>Gene Expression</i> , 2018 , 18, 149-155	3.4	9
39	Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patients in the ENETS registry.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4095-4095	2.2	2
38	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018 , 118, 181-188	8.7	15
37	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 276-282	2.2	357
36	Chemotherapy for pancreatic cancer: the rise of multidrug regimens. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 659-660	18.8	2
35	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 940-952	21.7	1120
34	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. <i>Neuroendocrinology</i> , 2017 , 105, 196-200	5.6	108
33	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. <i>Neuroendocrinology</i> , 2017 , 105, 295-309	5.6	142
32	Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. <i>European Journal of Cancer</i> , 2017 , 79, 158-165	7.5	53
31	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2017 , 49, 568-571	3.7	0
30	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	18
29	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 380-380	2.2	5
28	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017 , 8, 14408-14415	3.3	18
27	How to treat intestinal obstruction due to malignant recurrence after Whipple's resection for pancreatic head cancer: Description of 2 new endoscopic techniques. <i>World Journal of Gastroenterology</i> , 2017 , 23, 6181-6186	5.6	2

26	Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. <i>Targeted Oncology</i> , 2016 , 11, 667-675	5	22
25	Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): Feasibility results and early response monitoring by Diffusion-Weighted (DW) MR.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4116-4116	2.2	4
24	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016 , 7, 72622-72633	3.3	52
23	External validation of a prognostic score in patients (pts) with high-grade gastrointestinal neuroendocrine carcinomas (GI-NECs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4089-4089	2.2	
22	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4148-TPS4148	2.2	
21	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1844-53	27.4	538
20	Tetrahydro Iso-Alpha Acids and Hexahydro Iso-Alpha Acids from Hops Inhibit Proliferation of Human Hepatocarcinoma Cell Lines and Reduce Diethylnitrosamine Induced Liver Tumor Formation in Rats. <i>Nutrition and Cancer</i> , 2015 , 67, 748-60	2.8	5
19	Impact of Intraoperative Pancreatoscopy with Intraductal Biopsies on Surgical Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas. <i>Journal of the American College of Surgeons</i> , 2015 , 221, 982-7	4.4	16
18	Diagnostic and Therapeutic Roles of Endoscopic Ultrasound in Pediatric Pancreaticobiliary Disorders. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015 , 61, 238-47	2.8	48
17	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. <i>BMC Cancer</i> , 2013 , 13, 190	4.8	7
16	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 55-63	21.7	453
15	Significant impact of transient deterioration of renal function on dosimetry in PRRT. <i>Annals of Nuclear Medicine</i> , 2013 , 27, 74-7	2.5	8
14	Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. <i>Molecular Carcinogenesis</i> , 2012 , 51, 816-25	5	7
13	Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , 2011 , 364, 501-13	59.2	1817
12	Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. <i>Transplant International</i> , 2010 , 23, 668-78	3	43
11	Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1253-9	2.2	41
10	Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. <i>Chemico-Biological Interactions</i> , 2010 , 183, 238-48	5	16
9	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 378-90	59.2	9089

8	The Role of PPARgamma in Hepatocellular Carcinoma. <i>PPAR Research</i> , 2008 , 2008, 209520	4.3	16
7	Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. <i>Cancer Science</i> , 2007 , 98, 1831-9	6.9	11
6	Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. <i>Pancreatology</i> , 2005 , 5, 553-61	3.8	56
5	¹³¹ I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 905-10	2.2	15
4	The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma. <i>Hepatology</i> , 2003 , 37, 477-8; author reply 478	11.2	2
3	Use of 5-[(⁷⁶ Br)bromo-2Rfluoro-2Rdeoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002 , 29, 19-27	8.8	16
2	The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer. <i>Molecular Imaging and Biology</i> , 2000 , 3, 45-49		68
1	Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999 , 26, 591-8	8.8	54